Source:http://linkedlifedata.com/resource/pubmed/id/16721778
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2006-5-29
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1527-6465
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1020-1; author reply 1022-3
|
| pubmed:meshHeading | |
| pubmed:year |
2006
|
| pubmed:articleTitle |
Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post-liver transplant recipients.
|
| pubmed:publicationType |
Letter,
Comparative Study,
Comment
|